Advertisement

Photobiomodulation as a treatment for neurodegenerative disorders: current and future trends

  • Namgue HongEmail author
Review Article
  • 3 Downloads

Abstract

Photobiomodulation (PBM) is a rapidly growing as an innovative therapeutic modality for various types of diseases in recent years. Neuronal degeneration is irreversible process and it is proven to be difficult to slow down or stop the progression. Pharmacologic approaches to slow neuronal degeneration have been studied, but are limited due to concerns about the side effects. Therefore, it is necessary to develop a new therapeutic approach to stabilize neuronal degeneration and achieve neuronal protection against several neurodegenerative diseases. In this review, we have introduced several previous studies showing the positive effect of PBM over neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease and different types of epilepsy. Despite excellent outcomes of animal researches, not many clinical studies are conducted or showed positive outcome of PBM against neurodegenerative disease. To achieve clinical application of PBM against neurodegenerative disorder, determination of exact mechanism and establishment of effective clinical protocol seems to be necessary.

Keywords

Photobiomodulation Neurodegenerative diseases Alzheimer’s diseases Parkinson’s diseases Epilepsy 

Notes

Acknowledgements

The author thanks Prof. Jin-Chul Ahn and Dr. Min Young Lee for helpful comments on the manuscript.

Funding

This research was a part of the project titled ‘Development of marine material based near infrared fluorophore complex and diagnostic imaging instruments’, funded by the Ministry of Oceans and Fisheries, Korea (Grant Number 20170263), and also supported by the Ministry of Trade, Industry & Energy, Republic of Korea (Grant Numbers 20002777 and 20002831).

Compliance with ethical standards

Conflict of interest

The author declares no conflicts of interest.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

References

  1. 1.
    Hamblin MR. Shining light on the head: photobiomodulation for brain disorders. BBA Clin. 2016;6:113–24.Google Scholar
  2. 2.
    Hennessy M, Hamblin MR. Photobiomodulation and the brain: a new paradigm. J Opt. 2017;19(1):013003.Google Scholar
  3. 3.
    Naeser MA, Hamblin MR. Potential for transcranial laser or LED therapy to treat stroke, traumatic brain injury, and neurodegenerative disease. Photomed Laser Surg. 2011;29(7):443–6.Google Scholar
  4. 4.
    Naeser MA, Hamblin MR. Traumatic brain injury: a major medical problem that could be treated using transcranial, red/near-infrared LED photobiomodulation. Photomed Laser Surg. 2015;33(9):443–6.Google Scholar
  5. 5.
    Herrup K. The case for rejecting the amyloid cascade hypothesis. Nat Neurosci. 2015;18(6):794–9.Google Scholar
  6. 6.
    Nelson L, Tabet N. Slowing the progression of Alzheimer’s disease; what works? Ageing Res Rev. 2015;23(Pt B):193–209.Google Scholar
  7. 7.
    Goedert M. NEURODEGENERATION. Alzheimer’s and Parkinson’s diseases: the prion concept in relation to assembled Abeta, tau, and alpha-synuclein. Science. 2015;349(6248):1255555.Google Scholar
  8. 8.
    Braak H, Braak E. Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16(3):271–8 (discussion 8-84).MathSciNetGoogle Scholar
  9. 9.
    Goedert M, Spillantini MG. A century of Alzheimer’s disease. Science. 2006;314(5800):777–81.Google Scholar
  10. 10.
    Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–6.Google Scholar
  11. 11.
    Umeda T, Tomiyama T, Sakama N, Tanaka S, Lambert MP, Klein WL, et al. Intraneuronal amyloid beta oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J Neurosci Res. 2011;89(7):1031–42.Google Scholar
  12. 12.
    Gong CX, Iqbal K. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem. 2008;15(23):2321–8.Google Scholar
  13. 13.
    Brettschneider J, Del Tredici K, Lee VM, Trojanowski JQ. Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci. 2015;16(2):109–20.Google Scholar
  14. 14.
    Chaturvedi RK, Beal MF. Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci. 2008;1147:395–412.Google Scholar
  15. 15.
    Coppede F, Migliore L. DNA damage in neurodegenerative diseases. Mutat Res. 2015;776:84–97.Google Scholar
  16. 16.
    Cullen KM, Kocsi Z, Stone J. Pericapillary haem-rich deposits: evidence for microhaemorrhages in aging human cerebral cortex. J Cereb Blood Flow Metab. 2005;25(12):1656–67.Google Scholar
  17. 17.
    Cullen KM, Kocsi Z, Stone J. Microvascular pathology in the aging human brain: evidence that senile plaques are sites of microhaemorrhages. Neurobiol Aging. 2006;27(12):1786–96.Google Scholar
  18. 18.
    de la Torre JC. Is Alzheimer’s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 2004;3(3):184–90.Google Scholar
  19. 19.
    Gonzalez-Lima F, Barksdale BR, Rojas JC. Mitochondrial respiration as a target for neuroprotection and cognitive enhancement. Biochem Pharmacol. 2014;88(4):584–93.Google Scholar
  20. 20.
    Stone J. What initiates the formation of senile plaques? The origin of Alzheimer-like dementias in capillary haemorrhages. Med Hypotheses. 2008;71(3):347–59.Google Scholar
  21. 21.
    Stone J, Johnstone DM, Mitrofanis J, O’Rourke M. The mechanical cause of age-related dementia (Alzheimer’s disease): the brain is destroyed by the pulse. J Alzheimer’s Dis JAD. 2015;44(2):355–73.Google Scholar
  22. 22.
    Swerdlow RH, Khan SM. A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease. Med Hypotheses. 2004;63(1):8–20.Google Scholar
  23. 23.
    Galluzzi L, Kepp O, Trojel-Hansen C, Kroemer G. Mitochondrial control of cellular life, stress, and death. Circ Res. 2012;111(9):1198–207.Google Scholar
  24. 24.
    Begum R, Powner MB, Hudson N, Hogg C, Jeffery G. Treatment with 670 nm light up regulates cytochrome C oxidase expression and reduces inflammation in an age-related macular degeneration model. PLoS ONE. 2013;8(2):e57828.Google Scholar
  25. 25.
    Chung H, Dai T, Sharma SK, Huang YY, Carroll JD, Hamblin MR. The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng. 2012;40(2):516–33.Google Scholar
  26. 26.
    Desmet KD, Paz DA, Corry JJ, Eells JT, Wong-Riley MT, Henry MM, et al. Clinical and experimental applications of NIR-LED photobiomodulation. Photomed Laser Surg. 2006;24(2):121–8.Google Scholar
  27. 27.
    Gkotsi D, Begum R, Salt T, Lascaratos G, Hogg C, Chau KY, et al. Recharging mitochondrial batteries in old eyes. Near infra-red increases ATP. Exp Eye Res. 2014;122:50–3.Google Scholar
  28. 28.
    Liang HL, Whelan HT, Eells JT, Wong-Riley MT. Near-infrared light via light-emitting diode treatment is therapeutic against rotenone- and 1-methyl-4-phenylpyridinium ion-induced neurotoxicity. Neuroscience. 2008;153(4):963–74.Google Scholar
  29. 29.
    Rojas JC, Gonzalez-Lima F. Low-level light therapy of the eye and brain. Eye Brain. 2011;3:49–67.Google Scholar
  30. 30.
    Ying R, Liang HL, Whelan HT, Eells JT, Wong-Riley MT. Pretreatment with near-infrared light via light-emitting diode provides added benefit against rotenone- and MPP + -induced neurotoxicity. Brain Res. 2008;1243:167–73.Google Scholar
  31. 31.
    De Taboada L, Yu J, El-Amouri S, Gattoni-Celli S, Richieri S, McCarthy T, et al. Transcranial laser therapy attenuates amyloid-beta peptide neuropathology in amyloid-beta protein precursor transgenic mice. J Alzheimer’s Dis JAD. 2011;23(3):521–35.Google Scholar
  32. 32.
    Grillo SL, Duggett NA, Ennaceur A, Chazot PL. Non-invasive infra-red therapy (1072 nm) reduces beta-amyloid protein levels in the brain of an Alzheimer’s disease mouse model, TASTPM. J Photochem Photobiol, B. 2013;123:13–22.Google Scholar
  33. 33.
    Michalikova S, Ennaceur A, van Rensburg R, Chazot PL. Emotional responses and memory performance of middle-aged CD1 mice in a 3D maze: effects of low infrared light. Neurobiol Learn Mem. 2008;89(4):480–8.Google Scholar
  34. 34.
    Purushothuman S, Johnstone DM, Nandasena C, Eersel J, Ittner LM, Mitrofanis J, et al. Near infrared light mitigates cerebellar pathology in transgenic mouse models of dementia. Neurosci Lett. 2015;591:155–9.Google Scholar
  35. 35.
    Purushothuman S, Johnstone DM, Nandasena C, Mitrofanis J, Stone J. Photobiomodulation with near infrared light mitigates Alzheimer’s disease-related pathology in cerebral cortex—evidence from two transgenic mouse models. Alzheimers Res Ther. 2014;6(1):2.Google Scholar
  36. 36.
    da Luz Eltchechem C, Salgado ASI, Zangaro RA, da Silva Pereira MC, Kerppers II, da Silva LA, et al. Transcranial LED therapy on amyloid-beta toxin 25–35 in the hippocampal region of rats. Lasers Med Sci. 2017;32(4):749–56.Google Scholar
  37. 37.
    Sommer AP, Bieschke J, Friedrich RP, Zhu D, Wanker EE, Fecht HJ, et al. 670 nm laser light and EGCG complementarily reduce amyloid-beta aggregates in human neuroblastoma cells: basis for treatment of Alzheimer’s disease? Photomed Laser Surg. 2012;30(1):54–60.Google Scholar
  38. 38.
    Cosgrove J, Alty JE, Jamieson S. Cognitive impairment in Parkinson’s disease. Postgrad Med J. 2015;91(1074):212–20.Google Scholar
  39. 39.
    Bergman H, Deuschl G. Pathophysiology of Parkinson’s disease: from clinical neurology to basic neuroscience and back. Mov Disord. 2002;17(Suppl 3):S28–40.Google Scholar
  40. 40.
    Poewe W, Mahlknecht P, Jankovic J. Emerging therapies for Parkinson’s disease. Curr Opin Neurol. 2012;25(4):448–59.Google Scholar
  41. 41.
    Blandini F, Nappi G, Tassorelli C, Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson’s disease. Prog Neurobiol. 2000;62(1):63–88.Google Scholar
  42. 42.
    Rinne JO. Nigral degeneration in Parkinson’s disease. Mov Disord. 1993;8(Suppl 1):S31–5.MathSciNetGoogle Scholar
  43. 43.
    Blesa J, Phani S, Jackson-Lewis V, Przedborski S. Classic and new animal models of Parkinson’s disease. J Biomed Biotechnol. 2012;2012:845618.Google Scholar
  44. 44.
    Carvey PM, Hendey B, Monahan AJ. The blood–brain barrier in neurodegenerative disease: a rhetorical perspective. J Neurochem. 2009;111(2):291–314.Google Scholar
  45. 45.
    Corti O, Brice A. Mitochondrial quality control turns out to be the principal suspect in parkin and PINK1-related autosomal recessive Parkinson’s disease. Curr Opin Neurobiol. 2013;23(1):100–8.Google Scholar
  46. 46.
    Farkas E, De Jong GI, de Vos RA, Jansen Steur EN, Luiten PG. Pathological features of cerebral cortical capillaries are doubled in Alzheimer’s disease and Parkinson’s disease. Acta Neuropathol. 2000;100(4):395–402.Google Scholar
  47. 47.
    Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, Hill KJ, et al. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet. 2009;41(3):308–15.Google Scholar
  48. 48.
    Grammas P, Martinez J, Miller B. Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Rev Mol Med. 2011;13:e19.Google Scholar
  49. 49.
    Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, Willemsen AT, et al. Blood–brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol. 2005;57(2):176–9.Google Scholar
  50. 50.
    Exner N, Lutz AK, Haass C, Winklhofer KF. Mitochondrial dysfunction in Parkinson’s disease: molecular mechanisms and pathophysiological consequences. EMBO J. 2012;31(14):3038–62.Google Scholar
  51. 51.
    Fukae J, Mizuno Y, Hattori N. Mitochondrial dysfunction in Parkinson’s disease. Mitochondrion. 2007;7(1–2):58–62.Google Scholar
  52. 52.
    Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease. Lancet Neurol. 2009;8(1):67–81.Google Scholar
  53. 53.
    Bezard E, Yue Z, Kirik D, Spillantini MG. Animal models of Parkinson’s disease: limits and relevance to neuroprotection studies. Mov Disord. 2013;28(1):61–70.Google Scholar
  54. 54.
    Olanow CW, Kieburtz K, Schapira AH. Why have we failed to achieve neuroprotection in Parkinson’s disease? Ann Neurol. 2008;64(Suppl 2):S101–10.Google Scholar
  55. 55.
    Schapira AH, Olanow CW, Greenamyre JT, Bezard E. Slowing of neurodegeneration in Parkinson’s disease and Huntington’s disease: future therapeutic perspectives. Lancet. 2014;384(9942):545–55.Google Scholar
  56. 56.
    Vos M, Lovisa B, Geens A, Morais VA, Wagnieres G, van den Bergh H, et al. Near-infrared 808 nm light boosts complex IV-dependent respiration and rescues a Parkinson-related pink1 model. PLoS ONE. 2013;8(11):e78562.Google Scholar
  57. 57.
    Quirk BJ, Desmet KD, Henry M, Buchmann E, Wong-Riley M, Eells JT, et al. Therapeutic effect of near infrared (NIR) light on Parkinson’s disease models. Front Biosci. 2012;4:818–23.Google Scholar
  58. 58.
    Trimmer PA, Schwartz KM, Borland MK, De Taboada L, Streeter J, Oron U. Reduced axonal transport in Parkinson’s disease cybrid neurites is restored by light therapy. Mol Neurodegener. 2009;4:26.Google Scholar
  59. 59.
    El Massri N, Johnstone DM, Peoples CL, Moro C, Reinhart F, Torres N, et al. The effect of different doses of near infrared light on dopaminergic cell survival and gliosis in MPTP-treated mice. Int J Neurosci. 2016;126(1):76–87.Google Scholar
  60. 60.
    Johnstone DM, el Massri N, Moro C, Spana S, Wang XS, Torres N, et al. Indirect application of near infrared light induces neuroprotection in a mouse model of parkinsonism—an abscopal neuroprotective effect. Neuroscience. 2014;274:93–101.Google Scholar
  61. 61.
    Moro C, Massri NE, Torres N, Ratel D, De Jaeger X, Chabrol C, et al. Photobiomodulation inside the brain: a novel method of applying near-infrared light intracranially and its impact on dopaminergic cell survival in MPTP-treated mice. J Neurosurg. 2014;120(3):670–83.Google Scholar
  62. 62.
    Moro C, Torres N, El Massri N, Ratel D, Johnstone DM, Stone J, et al. Photobiomodulation preserves behaviour and midbrain dopaminergic cells from MPTP toxicity: evidence from two mouse strains. BMC Neurosci. 2013;14:40.Google Scholar
  63. 63.
    Peoples C, Spana S, Ashkan K, Benabid AL, Stone J, Baker GE, et al. Photobiomodulation enhances nigral dopaminergic cell survival in a chronic MPTP mouse model of Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(5):469–76.Google Scholar
  64. 64.
    Reinhart F, Massri NE, Chabrol C, Cretallaz C, Johnstone DM, Torres N, et al. Intracranial application of near-infrared light in a hemi-parkinsonian rat model: the impact on behavior and cell survival. J Neurosurg. 2016;124(6):1829–41.Google Scholar
  65. 65.
    Reinhart F, Massri NE, Darlot F, Torres N, Johnstone DM, Chabrol C, et al. 810 nm near-infrared light offers neuroprotection and improves locomotor activity in MPTP-treated mice. Neurosci Res. 2015;92:86–90.Google Scholar
  66. 66.
    Shaw VE, Keay KA, Ashkan K, Benabid AL, Mitrofanis J. Dopaminergic cells in the periaqueductal grey matter of MPTP-treated monkeys and mice; patterns of survival and effect of deep brain stimulation and lesion of the subthalamic nucleus. Parkinsonism Relat Disord. 2010;16(5):338–44.Google Scholar
  67. 67.
    El Massri N, Lemgruber AP, Rowe IJ, Moro C, Torres N, Reinhart F, et al. Photobiomodulation-induced changes in a monkey model of Parkinson’s disease: changes in tyrosine hydroxylase cells and GDNF expression in the striatum. Exp Brain Res. 2017;235(6):1861–74.Google Scholar
  68. 68.
    Ganeshan V, Skladnev NV, Kim JY, Mitrofanis J, Stone J, Johnstone DM. Pre-conditioning with remote photobiomodulation modulates the brain transcriptome and protects against MPTP insult in mice. Neuroscience. 2019;400:85–97.Google Scholar
  69. 69.
    Purushothuman S, Nandasena C, Johnstone DM, Stone J, Mitrofanis J. The impact of near-infrared light on dopaminergic cell survival in a transgenic mouse model of parkinsonism. Brain Res. 2013;1535:61–70.Google Scholar
  70. 70.
    Darlot F, Moro C, El Massri N, Chabrol C, Johnstone DM, Reinhart F, et al. Near-infrared light is neuroprotective in a monkey model of Parkinson disease. Ann Neurol. 2016;79(1):59–75.Google Scholar
  71. 71.
    Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med. 2011;365(10):919–26.Google Scholar
  72. 72.
    Wiebe S. Epidemiology of temporal lobe epilepsy. Can J Neurol Sci. 2000;27(Suppl 1):S6–10 (discussion S20-1).Google Scholar
  73. 73.
    ILAE Commission Report. The epidemiology of the epilepsies: future directions. International League Against Epilepsy. Epilepsia. 1997;38(5):614–8.Google Scholar
  74. 74.
    Cherian A, Thomas SV. Status epilepticus. Ann Indian Acad Neurol. 2009;12(3):140–53.Google Scholar
  75. 75.
    Knake S, Hamer HM, Rosenow F. Status epilepticus: a critical review. Epilepsy Behav E&B. 2009;15(1):10–4.Google Scholar
  76. 76.
    DeLorenzo RJ, Pellock JM, Towne AR, Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol. 1995;12(4):316–25.Google Scholar
  77. 77.
    Olney JW. Inciting excitotoxic cytocide among central neurons. Adv Exp Med Biol. 1986;203:631–45.Google Scholar
  78. 78.
    Sloviter RS, Dempster DW. “Epileptic” brain damage is replicated qualitatively in the rat hippocampus by central injection of glutamate or aspartate but not by GABA or acetylcholine. Brain Res Bull. 1985;15(1):39–60.Google Scholar
  79. 79.
    Patel MN. Oxidative stress, mitochondrial dysfunction, and epilepsy. Free Radic Res. 2002;36(11):1139–46.Google Scholar
  80. 80.
    Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov. 2010;9(1):68–82.Google Scholar
  81. 81.
    Berg AT, Shinnar S. Relapse following discontinuation of antiepileptic drugs: a meta-analysis. Neurology. 1994;44(4):601–8.Google Scholar
  82. 82.
    Schmidt D, Loscher W. Uncontrolled epilepsy following discontinuation of antiepileptic drugs in seizure-free patients: a review of current clinical experience. Acta Neurol Scand. 2005;111(5):291–300.Google Scholar
  83. 83.
    Ahmed NA, Radwan NM, Ibrahim KM, Khedr ME, El Aziz MA, Khadrawy YA. Effect of three different intensities of infrared laser energy on the levels of amino acid neurotransmitters in the cortex and hippocampus of rat brain. Photomed Laser Surg. 2008;26(5):479–88.Google Scholar
  84. 84.
    Radwan NM, El Hay Ahmed NA, Ibrahim KM, Khedr ME, Aziz MA, Khadrawy YA. Effect of infrared laser irradiation on amino acid neurotransmitters in an epileptic animal model induced by pilocarpine. Photomed Laser Surg. 2009;27(3):401–9.Google Scholar
  85. 85.
    Huang YY, Nagata K, Tedford CE, Hamblin MR. Low-level laser therapy (810 nm) protects primary cortical neurons against excitotoxicity in vitro. J Biophotonics. 2014;7(8):656–64.Google Scholar

Copyright information

© Korean Society of Medical and Biological Engineering 2019

Authors and Affiliations

  1. 1.Department of Pre-medical Science, College of MedicineDankook UniversityCheonanRepublic of Korea

Personalised recommendations